ABSTRACT
The most recent version of the octamethylcyclotetrasiloxane (D4) physiologically based pharmacokinetic (model) was developed using the available kinetic studies in male and female F344 rats. Additional data, which had not been included in the D4 model development, allowed for a more detailed assessment of the loss of D4 following long-term exposure in both SD and F344 rats. This new data demonstrated a deficiency in the published PBPK model predictions of terminal concentrations of D4 in plasma and fat 14 days after the end of exposures for 28-days, 6 h/day, where the model predictions were an order of magnitude lower than the data. To capture this time-point without altering the end-of-exposure peak concentrations in blood and fat required conversion of the one-way (liver to fat) mobile lipoprotein pool (MLP) into a bi-directional pool between liver and fat. Simulation of the D4 pharmacokinetics in the SD rat, as opposed to the F344 rat, also required a reduction of both fold induction of liver metabolism (KMAX: 5- to 2-fold) and maximal rate of metabolism (VMAXC: 5.0-1.54 mg/kg0.75). The revised MLP description was extended to the human D4 model using a parallelogram approach between rat and human MLP parameters to establish the parameters for the current model in the absence of similar long-term clearance data in the human. The revised human D4 model provided good fits to the human inhalation and dermal exposure studies while not appreciably altering cross-species dose metrics based on the free concentration of D4 in blood.
Subject(s)
Inhalation Exposure , Siloxanes , Rats , Male , Female , Humans , Animals , Rats, Inbred F344 , Inhalation Exposure/adverse effects , Siloxanes/toxicity , Siloxanes/pharmacokinetics , Kinetics , Rats, Sprague-Dawley , Models, Biological , LipidsABSTRACT
Octamethylcyclotetrasiloxane (D4), a highly lipophilic, volatile compound with low water solubility, is metabolized to lower molecular weight, linear silanols. Toxicity has been documented in several tissues in animals following mixed vapor/aerosol exposures by inhalation at near saturating vapor concentrations or with gavage dosing in vegetable oil vehicles. These results, together with more mechanism-based studies and detailed pharmacokinetic information, were used to assess likely modes of action (MOAs) and the tissue dose measures of D4 and metabolites that would serve as key events leading to these biological responses. This MOA analysis indicates that pulmonary effects arise from direct epithelial contact with mixed vapor/aerosol atmospheres of D4; liver hypertrophy and hepatocyte proliferation arise from adaptive, rodent-specific actions of D4 with nuclear receptor signaling pathways; and, nephropathy results from a combination of chronic progresive nephropathy and silanol metabolites binding with alpha-2u globulin (a male rat specific protein). At this time, the MOAs of other liver effects - pigment accumulation and bile duct hyperplasia (BDH) preferentially observed in Sprague-Dawley (SD) rats- are not known. Hypothalamic actions of D4 delaying the rat mid-cycle gonadotrophin releasing hormone (GnRH) surge that result in reproductive effects and subsequent vaginal/uterine/ovarian tissue responses, including small increases in incidence of benign endometrial adenomas, are associated with prolongation of endogenous estrogen exposures due to delays in ovulation. Human reproduction is not controlled by a mid-cycle GnRH surge. Since the rodent-specific reproductive and the vaginal/uterine/ovarian tissue responses are not relevant for risk assessments in human populations, D4 should neither be classified as a CMR (i.e., carcinogenic, mutagenic, or toxic for reproduction) substance nor be regarded as an endocrine disruptor. Bile duct hyperplasia (BDH) and pigment accumulation in liver seen in SD rats are endpoints that could serve to define a Benchmark Dose (BMD) or No-Observed-Effect-Level (NOEL) for D4 although their human relevance remains uncertain.
Subject(s)
Cell Proliferation/drug effects , Kidney/drug effects , Liver/drug effects , Lung/drug effects , Reproduction/drug effects , Siloxanes/pharmacokinetics , Siloxanes/toxicity , Animals , Carcinogens/toxicity , Dose-Response Relationship, Drug , Humans , Mutagens/toxicity , No-Observed-Adverse-Effect Level , Rats , Rats, Sprague-Dawley , Risk AssessmentABSTRACT
Organically modified silica (ORMOSIL) nanoparticles have found many biomedical applications and emerged as biocompatible and efficient carriers of diagnostic and therapeutic agents, such as fluorophores, drugs, and DNA. Herein, we describe two major in vivo studies exemplifying the use of these nanoparticles as carriers of active agents. The first part of this report details a systemic administration and biodistribution of radiolabeled and fluorophore-incorporated ORMOSIL nanoparticles in mice. The second part of this report focuses on the use of ORMOSIL nanoparticles as carriers of plasmid DNA for nonviral gene delivery to the mouse brain. We provide detailed protocols describing preparation and characterization of ORMOSIL nanoparticles, methods used for loading the particles with active agents (e.g., radioimaging agents, plasmid DNA), and in vivo administration of the particles.
Subject(s)
Brain/metabolism , Plasmids/administration & dosage , Siloxanes/chemistry , Animals , Biological Availability , Drug Delivery Systems , Female , Fluorescent Dyes/chemistry , Iodine Radioisotopes/chemistry , Mice , Nanoparticles , Plasmids/genetics , Plasmids/pharmacokinetics , Siloxanes/pharmacokineticsABSTRACT
Octamethylcyclotetrasiloxane (D4) is a volatile cyclic siloxane used primarily as a monomer or intermediate in the production of some silicon-based polymers widely used in industrial and consumer applications and may be present as a residual impurity in a variety of consumer products. A robust toxicological data set exists for D4. Treatment-related results from a chronic inhalation study conducted in rats are limited to mild effects on the respiratory tract, increases in liver weight, increases in the incidence of uterine endometrial epithelial hyperplasia, and a dose-related trend in the incidence of endometrial adenomas. The observed increases in liver weight appear to be related to the induction of hepatic metabolizing enzymes, similar to those that are induced in the presence of phenobarbital. D4 is not mutagenic or genotoxic in standard in vitro and in vivo tests; therefore, the benign uterine tumors observed likely occur by a non-genotoxic mechanism. Results from mechanistic studies suggest that D4 has very weak estrogenic and antiestrogenic activity, as well as dopamine agonist-like activity. In rats, D4 exposure delays ovulation and hypothesized to prolong exposure of the uterine endometrium to endogenous estrogen. Though this mode of action may play a role in the development of benign uterine tumors in the rat, it is considered unlikely to occur in the human due to the marked differences in cycle regulatory mechanisms. Reproductive effects were observed following D4 exposure in female rats. These effects appear to be related to a delay of the luteinizing hormone (LH) surge, which fails to induce complete ovulation in the rat. However, based on differences in ovulatory control in rats and humans, it appears these effects may be species-specific with no risk or relevance to human health. Results from pharmacokinetic studies indicate that dermal absorption of D4 is limited, due to its high volatility and, if absorbed via dermal, oral or inhalation exposure, the majority of D4 is rapidly cleared from the body, indicating bioaccumulation is unlikely.
Subject(s)
Environmental Pollutants/toxicity , Siloxanes/toxicity , Animals , Environmental Pollutants/administration & dosage , Environmental Pollutants/chemistry , Environmental Pollutants/pharmacokinetics , Humans , Molecular Structure , Siloxanes/administration & dosage , Siloxanes/chemistry , Siloxanes/pharmacokineticsABSTRACT
Octamethylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane (D5) are low molecular weight cyclic volatile methyl siloxanes (cVMSs) primarily used as intermediates or monomers in the production of high molecular weight silicone polymers. The use of D4 as a direct ingredient in personal care products has declined significantly over the past 20 years, although it may be present as a residual impurity in a variety of consumer products. D5 is still used as an intentional ingredient in cosmetics, consumer products and in dry cleaning. Persons who may be exposed include occupational exposure for workers, and potential inhalation or dermal exposure for consumers and the general public. Because of the diverse use, especially of D5, and the potential for human exposure, a comprehensive program was undertaken to understand the kinetics, metabolism, enzyme induction and toxicity of D4 and D5 in rats following relevant routes of exposure. Physiologically based pharmacokinetic (PBPK) models utilizing these studies have been reported for D4 and D5 in the rat and human following dermal and inhalation exposures, with the oral uptake component of the model being limited in its description. Data from high dose oral studies in corn oil and simethicone vehicles and neat were used in the D4/D5 harmonized PBPK model development. It was uncertain if the inability to adequately describe the oral uptake was due to unrealistic high doses or unique aspects of the chemistry of D4/D5. Low dose studies were used to provide data to refine the description of oral uptake in the model by exploring the dose dependency and the impact of a more realistic food-like vehicle. Absorption, distribution, metabolism and elimination (ADME) of D4 and D5 was determined following a single low oral gavage dose of 14C-D4 and 14C-D5 at 30 and 100mg/kg body weight (bw), respectively, in a rodent liquid diet. Comparison of the low vs. high dose oral gavage administration of D4 and D5 demonstrated dose-dependent kinetic behavior. Data and modeling results suggest differences in metabolism between low and high dose administration indicating high dose administration results in or approaches non-linear saturated metabolism. These low dose data sets were used to refine the D4/D5 multi-route harmonized PBPK model to allow for a better description of the disposition and toxicokinetics of D4/D5 following oral exposure. With a refined oral uptake description, the model could be used in risk assessment to better define the internal dose of D4 and D5 following exposure to D4 and D5 via multiple routes.
Subject(s)
Environmental Pollutants/metabolism , Siloxanes/metabolism , Adipose Tissue/chemistry , Administration, Inhalation , Adrenal Glands/chemistry , Animals , Area Under Curve , Carbon Isotopes , Environmental Pollutants/blood , Environmental Pollutants/chemistry , Environmental Pollutants/pharmacokinetics , Female , Gastrointestinal Tract/chemistry , Liver/chemistry , Lung/chemistry , Male , Ovary/chemistry , Rats , Rats, Inbred F344 , Siloxanes/chemistry , Siloxanes/pharmacokinetics , Spleen/chemistry , Testis/chemistry , Tissue Distribution , Uterus/chemistryABSTRACT
Critical factors (uptake, distribution, metabolism and elimination) for understanding the bioaccumulation/biomagnification potential of Octamethylcyclotetrasiloxane (D4) and Decamethylcyclopentasiloxane (D5) siloxanes in fish were investigated to address whether these chemicals meet the "B" criteria of the Persistent, Bioaccumulative, and Toxic (PBT) classification. A metabolism study was conducted in rainbow trout whereby a 15mg [14C]D4/kg bw or [14C]D5/kg bw as a single bolus oral dose was administered via gavage. Of the administered dose, 79% (D4) and 78% (D5) was recovered by the end of the study (96-h). Eighty-two percent and 25% of the recovered dose was absorbed based on the percentage of recovered dose in carcass (69% and 17%), tissues, bile and blood (12% and 8%) and urine (1%) for D4 and D5, respectively. A significant portion of the recovered dose (i.e. 18% for D4 and 75% for D5) was eliminated in feces. Maximum blood concentrations were 1.6 and 1.4µg D4 or D5/g blood at 24h post-dosing, with elimination half-lives of 39h (D4) and 70h (D5). Modeling of parent and metabolite blood concentrations resulted in estimated metabolism rate constants (km(blood)) of 0.15 (D4) and 0.17day-1(D5). Metabolites in tissues, bile, blood, and urine totaled a minimum of 2% (D4) and 14% (D5) of the absorbed dose. The highest concentration of 14C-activity in the fish following D4 administration was in mesenteric fat followed by bile, but the opposite was true for D5. Metabolites were not detected in fat, only parent chemical. In bile, 94% (D4) and 99% (D5) of the 14C-activity was due to metabolites. Metabolites were also detected in the digestive tract, liver and gonads. Approximately 40% of the 14C-activity detected in the liver was due to the presence of metabolites. Urinary elimination represented a minor pathway, but all the 14C-activity in the urine was associated with metabolites. Clearance may occur via enterohepatic circulation of metabolic products in bile with excretion via the digestive tract and urinary clearance of polar metabolites.
Subject(s)
Environmental Pollutants/metabolism , Siloxanes/metabolism , Administration, Oral , Animals , Carbon Isotopes , Environmental Pollutants/blood , Environmental Pollutants/pharmacokinetics , Environmental Pollutants/urine , Oncorhynchus mykiss , Prednisolone/analogs & derivatives , Siloxanes/pharmacokineticsABSTRACT
Decamethylcyclopentasiloxane (D5; CAS No. 541-02-6) is a precursor in the production of siloxane polymers for industry and medicine and is a carrier ingredient in many toiletries and cosmetics. D5 has a relatively low order of toxicity following acute administration via the oral, dermal, and inhalation routes of exposure. It is not considered to be a dermal or eye irritant or a dermal sensitizer. There is no appreciable dermal absorption of D5 based on results from in vivo and in vitro studies. It has not been shown to be genotoxic/mutagenic when tested in a number of short-term in vitro and in vivo assays and did not cause reproductive or developmental toxicity in rats. Inhalation exposure of rats to 160 ppm D5 for up to 24 months produced adverse effects in the liver (weight changes and hepatocellular hypertrophy) and uterus (increased incidence of endometrial adenocarcinoma, endometrial adenoma, and adenomatous polyps in several animals); however, the results of recent mode-of-action studies are consistent with a uterine tumorigenesis mechanism that is not relevant for humans. Based on the results of the chronic inhalation study, 160 ppm was determined to be the no-observed-adverse-effect level (NOAEL) and was selected as the point of departure for the derivation of the workplace environmental exposure level (WEEL®) value. This NOAEL was adjusted to account for interindividual variability and residual uncertainty regarding upper respiratory tract changes still occurring at 160 ppm. The resulting 8-h time-weighted average WEEL value of 10 ppm is expected to provide a significant margin of safety against any potential adverse health effects in workers exposed to airborne D5.
Subject(s)
Siloxanes/toxicity , Animals , DNA Damage/drug effects , Dose-Response Relationship, Drug , Female , Healthy Volunteers , Humans , Inhalation Exposure , Liver/drug effects , Male , No-Observed-Adverse-Effect Level , Rats , Siloxanes/pharmacokinetics , Toxicity Tests, Acute , Toxicity Tests, Chronic , Uterus/drug effectsABSTRACT
Octamethylcyclotetrasiloxane (D4; CAS No. 556-67-2) is used as a monomer in the manufacture of polymeric materials, which are widely used in various industrial and/or medical applications, such as breast implants. D4 has a relatively low order of toxicity following acute administration via the oral, dermal, and inhalation routes of exposure and is not considered to be a dermal or eye irritant or to be a dermal sensitizer. There is no appreciable dermal absorption of D4 based on results from in vivo and in vitro studies. D4 has not been shown to be genotoxic/mutagenic when tested in a number of short-term in vitro and in vivo assays. Overall, studies have demonstrated adverse effects on specific female reproductive endpoints at higher exposure concentrations; however, no D4 exposure-specific effects were noted with respect to developmental endpoints. Inhalation exposure of rats to 700 ppm D4 for up to 24 months produced effects in the liver, kidney, and uterus (weight changes, hepatocellular hypertrophy, endometrial hyperplasia, and nephropathy). Changes in the nasal epithelium (eosinophilic globules) were also noted at 150 and 700 ppm. Despite 24 months of exposure, only mild to minimal inflammatory responses were found at 150 ppm, and overall, the basic integrity of the respiratory tract was unchanged at this dose. At 700 ppm, there was an increased incidence of endometrial adenomas in female rats. Based on the adverse changes in the respiratory tract, kidney, and female reproductive tract in the chronic inhalation study, 150 ppm was determined to be the no-observed-adverse-effect level (NOAEL) and was selected as the point of departure for the derivation of the workplace environmental exposure level (WEEL®) value. The inhalation NOAEL was adjusted to account for interindividual variability and residual uncertainty regarding upper respiratory tract changes still occurring at 150 ppm. An 8-h time-weighted average WEEL value of 10 ppm is expected to provide a significant margin of safety against any potential adverse health effects in workers exposed to airborne D4.
Subject(s)
Siloxanes/toxicity , Animals , DNA Damage/drug effects , Dose-Response Relationship, Drug , Female , Humans , Inhalation Exposure , Kidney/drug effects , Kidney/metabolism , Liver/drug effects , Liver/metabolism , Male , Mice , No-Observed-Adverse-Effect Level , Rabbits , Rats , Siloxanes/pharmacokinetics , Toxicity Tests, Acute , Toxicity Tests, Chronic , Uterus/drug effects , Uterus/metabolismABSTRACT
Octamethylcyclotetrasiloxane (D4) is a cyclic siloxane primarily used as a monomer or intermediate in the production of silicone polymers resulting in potential exposure of workers, and potential low level inhalation or dermal exposure for consumers and the general public. Following a two-year inhalation toxicity study with D4 in rats, increases in uterine endometrial cystic hyperplasia and adenomas were observed at the highest concentration of D4 administered (700ppm). No other neoplasms were increased with D4 treatment. In addition, chronic inhalation exposure of rats to D4 induced changes in relative liver and kidney weights, and produced a chronic nephropathy. This manuscript examines the biological relevance and possible modes of action for the effects observed in the F344 rat following chronic inhalation exposure to D4. D4 is not genotoxic and appears to exert its effects through a nongenotoxic mode of action. An alteration in the estrous cycle in the aging F344 rat was the most likely mode of action for the observed uterine effects following chronic inhalation exposure. Data support the conclusion that D4 acts indirectly via a dopamine-like mechanism leading to alteration of the pituitary control of the estrous cycle in aging F344 rats with a decrease in progesterone and an increase in the estrogen/progesterone ratio most likely induced by a decrease in prolactin concentration. D4 also inhibited the pre-ovulatory LH surge causing a delay in ovulation, persistent follicles and thus a prolonged exposure to elevated estrogen in the adult Sprague Dawely rat. A lengthening of the estrous cycle in the F344 rat with an increase in endogenous estrogen was also induced by D4 inhalation. Although the mode of action responsible for induction of uterine adenomas in the female F344 rat has not been clearly confirmed, the subtlety of effects on the effects of D4 on cyclicity may prevent further assessment and definition of the mode of action. The occurrence of uterine endometrial adenoma in the rat is not relevant for human risk characterization because (1) there are differences in ovulatory cycle regulation in rats compared to humans, (2) cystic hyperplasia without atypia in women is not a cancer precursor, and (3) there is no endometrial lesion in women that is directly analogous to endometrial adenoma in the rat. The effects of D4 on liver are due to a phenobarbital-like mechanism that results in induction of cytochrome P450 and other enzymes of xenobiotic biotransformation. The liver effects are adaptive and not adverse. Kidney findings included chonic progressive nephropathy, a rat lesion that has no counterpart in the human and that should not be used in human risk assessment.
Subject(s)
Endometrial Neoplasms/chemically induced , Liver/drug effects , Siloxanes/toxicity , Administration, Inhalation , Animals , Drug Administration Schedule , Estrous Cycle/drug effects , Female , Liver/anatomy & histology , Organ Size , Rats , Rats, Inbred F344 , Siloxanes/administration & dosage , Siloxanes/chemistry , Siloxanes/pharmacokineticsABSTRACT
There are currently seven published physiologically based pharmacokinetic (PBPK) models describing aspects of the pharmacokinetics of octamethylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane (D5) for various exposure routes in rat and human. Each model addressed the biological and physico-chemical properties of D4 and D5 (highly lipophilic coupled with low blood: air partition coefficient and high liver clearance) that result in unique kinetic behaviors as well differences between D4 and D5. However, the proliferation of these models resulted in challenges for various risk assessment applications when needing to determine the optimum model for estimating dose metrics. To enhance the utility of these PBPK models for risk assessment, we integrated the suite of structures into one coherent model capable of simulating the entire set of existing data equally well as older more limited scope models. In this paper, we describe the steps required to develop this integrated model, the choice of physiological, partitioning and biochemical parameters for the model, and the concordance of the model behavior across key data sets. This integrated model is sufficiently robust to derive relevant dose metrics following individual or combined dermal and inhalation exposures of workers, consumer or the general population to D4 and D5 for route-to-route, interspecies and high to low dose extrapolations for risk assessment.
Subject(s)
Models, Biological , Siloxanes/pharmacokinetics , Adipose Tissue/metabolism , Animals , Female , Humans , Inhalation Exposure , Liver/metabolism , Male , Rats , Risk Assessment , Skin/metabolism , Tissue Distribution , VolatilizationABSTRACT
Decamethylcyclopentasiloxane (D5) is a cyclic siloxane used in the formulation of consumer products as well as an industrial intermediate. A summary of the previous studies on the toxicology of D5 is provided. Toxicokinetic studies with D5 after dermal administration demonstrate a very low uptake of due to rapid evaporation. Following inhalation exposure, exhalation of unchanged D5 and excretion of metabolites with urine are major pathways for clearance in mammals. Due to this rapid clearance by exhalation, the potential for bioaccumulation of D5 is considered unlikely. The available toxicity data on D5 adequately cover the relevant endpoints regarding potential human health hazards. D5 was not DNA reactive or mutagenic in standard in vitro and in vivo test systems. D5 also did not induce developmental and reproductive toxicity in appropriately performed studies. In repeated studies in rats with subacute, subchronic and chronic inhalation exposure, mild effects on the respiratory tract typically seen after inhalation of irritating materials, increases in liver weight (28- and 90-day inhalation studies), and a small increase in the incidence of uterine adenocarcinoma (uterine tumor) in female rats (two-year inhalation chronic bioassay) were observed. The liver effects induced by D5 were consistent with D5 as a weak "phenobarbital-like" inducer of xenobiotic metabolizing enzymes and these effects are considered to be an adaptive response. Mechanistic studies to elucidate the mode-of-action for uterine tumor induction suggest an interaction of D5 with dopamine signal transduction pathways altering the pituitary control of the estrus cycle. The resulting estrogen imbalance may cause the small increase in uterine tumor incidence at the highest D5-exposure concentration over that seen in control rats. A genotoxic mechanism or a direct endocrine activity of D5 is not supported as a mode-of-action to account for the induction of uterine tumors by the available data.
Subject(s)
Siloxanes/toxicity , Adenocarcinoma/chemically induced , Animals , Endometrial Neoplasms/chemically induced , Female , Humans , Liver/drug effects , Liver/pathology , Respiratory System/drug effects , Respiratory System/pathology , Siloxanes/pharmacokineticsABSTRACT
Decamethylcyclopentasiloxane (D5) is a low-molecular-weight cyclic siloxane used primarily as an intermediate in the production of several widely-used industrial and consumer products and intentionally added to consumer products, personal products and some dry cleaning solvents. The global use requires consideration of consumer use information and risk assessment requirements from various sources and authoritative bodies. A global "harmonized" risk assessment was conducted to meet requirements for substance-specific risk assessments conducted by regulatory agencies such as USEPA's Integrated Risk Information System (IRIS), Health Canada and various independent scientific committees of the European Commission, as well as provide guidance for chemical safety assessments under REACH in Europe, and other relevant authoritative bodies. This risk assessment incorporates global exposure information combined with a Monte Carlo analysis to determine the most significant routes of exposure, utilization of a multi-species, multi-route physiologically based pharmacokinetic (PBPK) model to estimate internal dose metrics, benchmark modeling to determine a point of departure (POD), and a margin of safety (MOS) evaluation to compare the estimates of intake with the POD. Because of the specific pharmacokinetic behaviors of D5 including high lipophilicity, high volatility with low blood-to-air partition coefficients and extensive metabolic clearance that regulate tissue dose after exposure, the use of a PBPK model was essential to provide a comparison of a dose metric that reflects these processes. The characterization of the potential for adverse effects after exposure to D5 using a MOS approach based on an internal dose metric removes the subjective application of uncertainty factors that may be applied across various regulatory agencies and allows examination of the differences between internal dose metrics associated with exposure and those associated with adverse effects.
Subject(s)
Siloxanes/toxicity , Adolescent , Adult , Animals , Child , Child, Preschool , Dose-Response Relationship, Drug , Environmental Exposure/analysis , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Models, Biological , Monte Carlo Method , Risk Assessment , Siloxanes/pharmacokinetics , Young AdultABSTRACT
Decamethylcyclopentasiloxane (D5) is a cyclic polydimethylsiloxane used in the synthesis of silicon-based materials and as a component in consumer products. Male and female Fischer 344 rats were exposed to D5 vapor (0, 10, 40, 160 ppm; whole-body inhalation) for 6 h/d, 5 d/wk, for up to 104 weeks. Microscopic examination of tissues revealed test article effects at 160 ppm in the upper respiratory tract (hyaline inclusions in males and females at 6, 12, and 24 months) and an increased incidence of uterine endometrial adenocarcinoma at 24-months. The hyaline inclusions were considered a non-adverse tissue response for lack of any other respiratory tract non-neoplastic or neoplastic changes. Uterine endometrial adenocarcinoma was not anticipated. Toxicity testing (mutagenicity/genotoxicity, acute, sub-acute and sub-chronic descriptive toxicity) performed prior to the conduct of the chronic bioassay provided no indication that the uterus was a potential target organ. The target organ and tumor type specificity (adenocarcinoma is a common spontaneous tumor in the aged Fischer 344 rat) suggests the effect is associated with estrous cycle alteration. A robust assessment of potential mode(s) of action responsible for the uterine tumors and relevance to humans is addressed in a companion manuscript (Klaunig et al., 2015).
Subject(s)
Adenocarcinoma/chemically induced , Endometrial Neoplasms/chemically induced , Siloxanes/toxicity , Adenocarcinoma/pathology , Administration, Inhalation , Animals , Carcinogenicity Tests , Endometrial Neoplasms/pathology , Endometrium/drug effects , Endometrium/pathology , Female , Male , Rats, Inbred F344 , Respiratory System/drug effects , Respiratory System/pathology , Siloxanes/pharmacokinetics , Species Specificity , Toxicity Tests, ChronicABSTRACT
Consumer exposure to leave-on cosmetics and personal care products (C&PCPs) ingredients of low or moderate volatility is often assumed to occur primarily via dermal absorption. In reality they may volatilize from skin and represent a significant source for inhalation exposure. Often, evaporation rates of pure substances from inert surfaces are used as a surrogate for evaporation from more complex product matrices. Also the influence of partitioning to skin is neglected and the resulting inaccuracies are not known. In this paper we describe a novel approach for measuring chemical evaporation rates from C&PCPs under realistic consumer exposure conditions. Series of experiments were carried out in a custom-made ventilated chamber fitted with a vapor trap to study the disposition of a volatile cosmetic ingredient, decamethylcyclopentasiloxane (D5), after its topical application on either aluminum foil or porcine skin in vitro. Single doses were applied neat and in commercial deodorant and face cream formulations at normal room (23°C) and skin temperature (32°C). The condition-specific evaporation rates were determined as the chemical mass loss per unit surface area at different time intervals over 1-1.25h post-dose. Product weight loss was monitored gravimetrically and the residual D5 concentrations were analyzed with GC/FID. The release of D5 from exposed surfaces of aluminum occurred very fast with mean rates of 0.029 mg cm(-2)min(-1) and 0.060 mg cm(-2)min(-1) at 23°C and 32°C, respectively. Statistical analysis of experimental data confirmed a significant effect of cosmetic formulations on the evaporation of D5 with the largest effect (2-fold decrease of the evaporation rate) observed for the neat face cream pair at 32°C. The developed approach explicitly considers the initial penetration and evaporation of a substance from the Stratum Corneum and has the potential for application in dermal exposure modeling, product emission tests and the formulation of C&PCPs.
Subject(s)
Cosmetics/analysis , Inhalation Exposure/analysis , Models, Biological , Siloxanes/analysis , Administration, Cutaneous , Animals , Cosmetics/pharmacokinetics , Humans , In Vitro Techniques , Siloxanes/pharmacokinetics , Skin , Skin Absorption , Swine , VolatilizationABSTRACT
In this study, hybrid silica xerogel particles were developed as carriers of budesonide (BDS) for efficient local treatment of inflammatory bowel diseases (IBD). Organically modified silica particles (ORMOSILs) were prepared by co-condensation of 3-aminopropyltriethoxysilane (APTES) and tetraethyl orthosilicate (TEOS) by an ambient temperature acid catalysed sol-gel process followed by spray-drying. Formulation for preparation of BDS-loaded particles was optimized and their physicochemical parameters and drug release profiles were evaluated in vitro. Optimal formulation had a small particle size (mean diameter of 1.45±0.02µm) with unimodal narrow size distribution and high encapsulation efficiency (98.0 ± 1.85%). Due to the positive surface charge originated from amino group of APTES, ORMOSILs showed excessive mucoadhesiveness in comparison to native TEOS particles. The drug release decreased with increasing pH from 2.0 to 7.4. In order to avoid undesirable erroneous performance in the upper GI tract, particles were additionally coated with Eudragit(®) FS 30D, as a barrier to the drug release at pH range from 2.0 to 7.0. After Eudragit(®) FS 30D coating, the release of BDS in acidic media was sustained, while no significant differences in drug release were observed at pH 7.4. In conclusion, pH-responsive ORMOSILs showed great potential for efficient BDS delivery to the colon region.
Subject(s)
Budesonide/chemistry , Budesonide/pharmacokinetics , Colon/metabolism , Drug Delivery Systems/methods , Siloxanes/chemistry , Siloxanes/pharmacokinetics , Animals , Budesonide/administration & dosage , Chemistry, Pharmaceutical , Colon/drug effects , Female , Particle Size , Rats , Rats, Wistar , Siloxanes/administration & dosageABSTRACT
Consumers who use personal care products (PCPs) are internally exposed to some of the organic components present of which some may be detected in exhaled air when eliminated. The aim of this study was the quantitative determination of octamethylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane (D5) in end-exhaled air to study dermal absorption of substances in PCPs. We exposed the forearm of fifteen healthy volunteers for 60min to pure D4 or D5 and to commercial products containing D4 and D5. Inhalation uptake was kept to a minimum by keeping the forearm in a flow cabinet during dermal exposure and supplying filtered air to the breathing zone of the volunteer during the post-exposure period. End-exhaled air was collected using a breath sampler (Bio-VOC), transferred to carbograph multi-bed adsorbent tubes and analyzed by thermal desorption gas chromatography mass spectrometry (TD-GC-MS). In the end-exhaled air of non-exposed volunteers background concentrations of D4 (0.8-3.5ng/L) and D5 (0.8-4.0ng/L) were observed. After exposing the volunteers, the level of D4 and D5 in end-exhaled air did not or barely exceed background concentrations. At t=90min, a sharp increase of the D4/D5 concentration in end-exhaled air was observed, which we attributed to the inhalation of the substances during a toilet visit without using inhalation protection devices. When this visit was taken out of the protocol, the sharp increase disappeared. Overall, the results of our study indicate that dermal absorption of D4 and D5 contributes only marginally to internal exposure following dermal applications. As in our study inhalation is the primary route of entry for these compounds, we conclude that its risk assessment should focus on this particular exposure route.
Subject(s)
Cosmetics , Dermis/metabolism , Siloxanes/pharmacokinetics , Administration, Cutaneous , Adult , Cosmetics/administration & dosage , Female , Gas Chromatography-Mass Spectrometry , Humans , Inhalation Exposure , Male , Middle Aged , Risk Assessment , Siloxanes/administration & dosage , Siloxanes/analysis , Skin AbsorptionABSTRACT
ORganically MOdified SILica (ORMOSIL) nanoparticles (NPs) appear promising carriers for the delivery of drugs to target tissues but concerns on possible cytotoxic effects exist. Here, we studied the in vitro responses to ORMOSIL NPs in different types of human lung cells to determine the effects of polyethylene glycol (PEG) coating on NP cytotoxicity. Non-PEG NPs caused a concentration-dependent decrease of viability of all types of cells, while PEG NPs induced deleterious effects and death in carcinoma alveolar type II A549 cells but not in CCD-34Lu fibroblasts and NCI-H2347 adenocarcinoma cells. Reactive oxygen species were detected in cells incubated with PEG NPs, but their deactivation by superoxide dismutase and catalase did not protect A549 cells from death, suggesting that the oxidative stress was not the main determinant of cytotoxicity. Only in A549 cells PEG NPs modulated the transcription of genes involved in inflammation, signal transduction and cell death. Transmission electron microscopy evidenced a unique intracellular localization of PEG NPs in the lamellar bodies of A549 cells, which could be the most relevant factor leading to cytotoxicity by reducing the production of surfactant proteins and by interfering with the pulmonary surfactant system.
Subject(s)
Drug Carriers/pharmacology , Lung/drug effects , Nanoparticles/chemistry , Polyethylene Glycols/pharmacology , Siloxanes/pharmacology , Cell Culture Techniques , Cell Line, Tumor , Cell Membrane Permeability/drug effects , Cell Survival/drug effects , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Fibroblasts/drug effects , Fibroblasts/metabolism , Fibroblasts/pathology , Humans , Lung/metabolism , Lung/pathology , Microscopy, Electron, Scanning , Microscopy, Electron, Transmission , Particle Size , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Pulmonary Surfactants/metabolism , Reactive Oxygen Species/metabolism , Siloxanes/chemistry , Siloxanes/pharmacokinetics , Surface Properties , Transcriptome/drug effectsABSTRACT
Studies have shown that some cyclic methyl siloxanes were identified as characterized of persistent, bioaccumulated, toxic, and potential to ecological harm. In this study, we determined methyl siloxanes in seawater, sediment and bottom fish samples collected from marine environment in Northeast China. The mean concentrations of total methyl siloxanes were 46.1 ± 27.2 ng/L, 12.4 ± 5.39 ng/g dry weight (dw) and 5.10 ± 1.34 wet weight (ww) in seawater, sediment and fish, respectively. Very strong and significant correlations (r = 0.94, p < 0.0001) were found in compositions of methyl siloxanes between seawater and sewage, indicating that sewage was the main source of methyl siloxanes in the marine area studied. It was found that the mean value of biota-sediment accumulation factor (BSAF) was.0.716 ± 0.456 for D4, 0.103 ± 0.0771 for D5, 1.06 ± 0.528 for D6 and 0.877 ± 0.530 for D7.
Subject(s)
Fishes/metabolism , Geologic Sediments/chemistry , Seawater/chemistry , Siloxanes/chemistry , Animals , China , Sewage/chemistry , Siloxanes/analysis , Siloxanes/pharmacokinetics , Water Pollutants, Chemical/analysisABSTRACT
Gelatin-siloxane nanoparticles (GS NPs) have been considered to be good gene carrier candidate in vitro, since they have several advantages such as low toxicity, easy preparation and surface modification. In this study, the Tat-PEG-GS NPs were synthesized by the gelatin-siloxane, surface-modified with the polyethylene glycol (H2 N-PEG-COOH) and Tat peptide (KYGRRRQRRKKRGC) and thus constructed a delivery system which can cross BBB (Blood-brain barrier). The morphology, diameter, and zeta potential of Tat-PEG-GS NPs carrier system were characterized with transmission electron microscopy (TEM) and Nano-ZS zetasizer dynamic light scattering Detector. The organ distribution and dynamic evolution localized in the brain parenchyma of Tat-PEG-GS NPs in vivo was investigated with Cri in vivo imaging system and TEM. The obtained Tat-PEG-GS NPs were approximately spherical in shape with average particle size of 150-200 nm and zeta potentials of (32.27 +/- 2.47) mV. In vivo imaging results showed that the accumulation of Tat-PEG-GS NPs was higher in the brain than the accumulation of PEG-GS NPs, but the accumulation of Tat-PEG-GS NPs was lower in the liver than the accumulation of PEG-GS NPs. These differences are statistically significant. The nanocomplex could cross the BBB and reach the neural tissues tested with TEM. The Tat-PEG-GS NPs could cross the BBB and escape the arrest of the reticuloendothelial system (RES), and it would be potential nano-carrier systems for central delivery.